For research and educational purposes only. Not medical advice.

Orforglipron Reference

Educational, not medical advice reference for Orforglipron: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule no…

Reference summary

Wharton 2025 NEJM (ATTAIN-1, Phase 3, adults with obesity, 72 weeks) reported approximately 11 percent mean weight loss at the highest dose - smaller than the magnitudes seen with injectable semaglutide and tirzepatide pivotal trials but meaningful for an oral, non-peptide product that does not require the food / water timing restrictions of oral semaglutide (Rybelsus). Phase 3 ACHIEVE trials in type 2 diabetes reported A1c reductions broadly consistent with the GLP-1 class. The principal practical advantage of orforglipron is the oral non-peptide formulation; the principal practical tradeoff versus injectable analogs is a somewhat smaller magnitude of effect.

Regulatory and posture

Categories
GLP-1, Fat Loss
Aliases
LY3502970, Oral non-peptide small-molecule GLP-1 receptor agonist
Evidence posture
human
Regulatory status
FDA-approved. The FDA approved Foundayo (orforglipron), Eli Lilly's oral non-peptide small-molecule GLP-1 receptor agonist, on April 1, 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity. Unlike oral semaglutide (Rybelsus), it can be taken at any time of day without food or water restrictions. The Phase 3 development program was ACHIEVE (type 2 diabetes) and ATTAIN (obesity).
Content review status
label verified

Selected public sources

Related tools